TDAP vaccine: When to get it, side effects, and safety
Should People 65 And Older Get The Pneumonia Vaccine?
Dear Savvy Senior: I recently turned 65 and would like to know if I am supposed to get the pneumonia vaccine? And if so, which type of vaccine do I need, and is it covered by Medicare? — Relatively Healthy
Dear Relatively Healthy: Yes, the Centers for Disease Control and Prevention recommends pneumococcal vaccines for people 65 and older. They're also recommended for younger people with long-term health issues or weak immune systems, as well as children under 5 and people who smoke.
Pneumonia, which can happen anytime — not just during the cold months — can be a serious and even life-threatening condition. Each year, pneumonia leads a whopping 1.5 million people to visit medical emergency departments in the U.S. And causes roughly 50,000 deaths.
A recent study found that the use of pneumonia vaccines is associated with a 24 percent decrease in the risk of death, but vaccination rates aren't that high.
Around 67 percent of adults over age 65 are vaccinated against pneumonia, and just 24 percent of younger people (19-64 years old) at risk for pneumonia are vaccinated. Many people are unsure whether they need the vaccine, while others aren't even aware a vaccine exists.
Types of vaccines
There are three vaccines available, some more appropriate for certain people than others. They are the pneumococcal polysaccharide vaccine PPSV23 (Pneumovax23), the pneumococcal conjugate vaccine PCV15 (Vaxneuvance) and PCV20 (Prevnar 20). The numbers indicate how many strains, or serotypes, of streptococcus pneumoniae are included in the vaccine.
So, which vaccine should you get?
If you've never been vaccinated for pneumonia, the newer PCV20 is the top choice — it covers the 20 most common serotypes.
If that vaccine is not available in your area, you can get the PCV15 vaccine, followed one year later by PPSV23.
If you had the earlier PCV13 (but not PCV15), or the PPSV23 at or after age 65, you're probably eligible to get the PCV20 for increased protection.
Talk to your doctor or pharmacist about the most effective option for you.
Side effects of these vaccines tend to be mild but may include feeling achy and tired, as well as redness, swelling and soreness at the injection site.
Medicare Part B covers single-dose and two-dose pneumococcal shots, and you only need to get it once, unlike the flu shot, which is given annually.
Most local pharmacies and community health clinics offer pneumococcal vaccines, but you may want to call ahead to be sure.
Visit CDC.Gov for more information.
Other vaccines
To avoid getting pneumonia as a consequence of a viral infection, you should also consider getting a flu shot, RSV shot and a COVID-19 booster in the fall.
While vaccines cannot prevent every case of pneumonia (or other conditions they're given for), those who get them usually have milder infections, a shorter course of illness and fewer serious complications.
The flu shot and COVID booster are covered by Medicare Part B, while the RSV vaccine (which is recommended every other year) is covered under Medicare Part D prescription drug plans. All three shots can be given simultaneously.
Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.Org.
Pneumococcal Vaccine Research Report 2024: Market Expected To Reach $12.932 Billion By 2029
Company Logo
Pneumococcal Vaccines Market
Pneumococcal Vaccines Market
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Pneumococcal Vaccines Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.Com's offering.
The global pneumococcal vaccine market is undergoing significant growth, driven by heightened awareness and initiatives targeting pneumonia prevention. The increasing implementation of vaccination programs under national health policies promises to broaden market prospects and enhance protection against the pernicious effects of the Streptococcus pneumoniae bacteria, particularly amongst the most vulnerable populations, including young children, adults, and the elderly. The concerted efforts of global health organizations complement government support, propelling the market forward.
The North American region stands out as a substantial contributor to the global pneumococcal vaccine market, underpinned by robust regulatory approvals and a focus on pediatric health and elderly immunization strategies. The market's vigor is fueled by continuous advancements in vaccine research and development, alongside strategic collaborations that aim to satisfy the burgeoning demand for effective prophylactic measures against pneumococcal diseases.
Technological Advancements in Vaccine Development
Innovative strides in vaccine technology have led to an upswing in the conjugate vaccines sector, which is anticipated to display exceptional growth. These vaccines offer enhanced immunity for a spectrum of diseases, including pneumonia and meningitis. Recent approvals by the FDA signal a strong commitment to combating invasive pneumococcal disease through developments such as Pfizer's PREVNAR 20® and Merck's CAPVAXIVE™.
Architects of Change: Government and Organizational Policies
Integral to the growth of the pneumococcal vaccine market is the role of health policies and awareness campaigns led by governments, supported by international organizations such as the WHO, UNICEF, and the UNDP. These initiatives enhance disease comprehension and vaccination uptake, particularly in underdeveloped regions with prolific pneumonia incidence rates.
Market Challenges and Strategies
While the pneumococcal vaccine market is expanding, challenges related to the high cost and complexities of vaccine production persist. However, subsidies and substantial funding allocations by governments and international bodies are actively addressing these barriers, streamlining the path to market growth and accessibility.
Key Market Developments
Recent milestones achieved in the pneumococcal vaccine landscape are shaping a more resilient future in disease prevention. Pfizer's garnering of the CHMP's positive opinion and Vaxcyte Inc.'s commercial manufacturing agreement with Lonza represent significant advancements that promise enhanced protection against pneumococcal diseases across demographics. The global pneumococcal vaccine market is diversifying and entering a dynamic era of growth and innovation. This positive trend holds the potential to significantly impact public health outcomes, particularly in the fight against severe pneumonia and related diseases worldwide.
Key Attributes:
Story continues
Report Attribute
Details
No. Of Pages
110
Forecast Period
2024 - 2029
Estimated Market Value (USD) in 2024
$9.44 Billion
Forecasted Market Value (USD) by 2029
$12.93 Billion
Compound Annual Growth Rate
6.4%
Regions Covered
Global
Companies Featured
For more information about this report visit https://www.Researchandmarkets.Com/r/gjzbnm
About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.Com Laura Wood,Senior Press Manager press@researchandmarkets.Com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900View comments
SAVVY SENIOR: If You're 65 Or Older, It's Time To Get Your Pneumonia Shot
I recently turned 65 and would like to know if am supposed to get the pneumonia vaccine? And if so, which type of vaccine do I need and is it covered by Medicare?
Relatively HealthyDear Relatively,
Yes, the Centers for Disease Control and Prevention does indeed recommend the "pneumococcal vaccines" for pneumonia for adults age 65 and older. They're also recommended for younger people with long-term health issues or weak immune systems, as well as children age 5 and younger and people who smoke.
Pneumonia, which can happen anytime – not just during the cold months – can be a serious and even life-threatening condition. Each year, pneumonia causes a whopping 1.5 million people to visit medical emergency departments in the U.S. And causes roughly 50,000 deaths.
People are also reading…
A recent study found that the use of pneumonia vaccines is associated with a 24% decreased risk of death, but vaccination rates aren't that high.
Around 67% of adults older than age 65 are vaccinated against pneumonia, and just 24% of younger people, age 19-64, at risk for pneumonia are vaccinated. The main reasons for this are because many people are unsure whether they need the vaccine, while others aren't even aware a vaccine exists.
Types of vaccinesThere are three different vaccines available, some more appropriate for certain people than others. They are the pneumococcal polysaccharide vaccine PPSV23 or Pneumovax23; the pneumococcal conjugate vaccine PCV15 or Vaxneuvance; and PCV20 or Prevnar 20. The numbers indicate how many strains, or serotypes, of streptococcus pneumoniae are included in the vaccine.
So, which vaccine should you get?If you've never been vaccinated for pneumonia, the newer PCV20 is the top choice – it covers the 20 most common serotypes now.
If that vaccine is not available in your area, you can get the PCV15 vaccine, followed one year later by PPSV23.
If you had the earlier PCV13—but not PCV15, or the PPSV23 at or after age 65, you're likely eligible to get the PCV20 for increased protection.
But because of the different possibilities, you need to talk to your doctor or pharmacist about the most effective option for you.
Side effects of these vaccines tend to be mild, but may include feeling achy and tired as well as redness, swelling and soreness where the injection was given.
You'll also be happy to know that Medicare Part B covers both single dose and two-dose pneumococcal shots, and you only need to get it once. Unlike the flu shot, which is given annually.
Most local pharmacies and community health clinics offer pneumococcal vaccines, but you may want to call ahead just to be sure.
For more information, visit the CDC's Pneumococcal Vaccination webpage at cdc.Gov/vaccines/vpd/pneumo/index.Html.
Other vaccinesTo avoid getting pneumonia as a consequence of a viral infection, you should also consider getting a flu shot, RSV shot and a Covid-19 booster in the fall.
While vaccines cannot prevent every case of pneumonia—or other conditions they're given for, those who get them usually have milder infections, a shorter course of illness and fewer serious complications than people who don't get vaccinated.
The flu shot and Covid booster are both covered by Medicare Part B, while the RSV vaccine—which is recommended every other year—is covered under Medicare Part D prescription drug plans. All three shots can also be given simultaneously.
Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit savvysenior.Org. Jim Miller is a contributor to the NBC Today show and author of "The Savvy Senior" book.
Receive the latest in local entertainment news in your inbox weekly!
Comments
Post a Comment